bioRxivBiophysicsPreprint
Structural basis for the access and binding of resolvin D1 (RvD1) to formyl peptide receptor 2 (FPR2/ALX), a class A GPCR
Brian Mun, Peter Obi, Christopher T. Szlenk, Senthil NatesaniD
Abstract
Inflammation is essential to the bodys defense against tissue injury and microbial invasion. However, uncontrolled inflammation is highly detrimental and can result in chronic inflammatory diseases such as asthma, cancer, obesity, and diabetes. An increasing body of evidence suggests that specialized pro-resolving lipid mediators (SPMs), such as resolvins, are actively involved in critical cellular events that drive the resolution of inflammation and a return to homeostasis. An imbalance caused by insufficient SPMs can result in the unsuccessful resolution of inflammation. The D-series resolvins (metabolites of docosahexaenoic acid), such as resolvin D1 (RvD1) and resolvin D2 (RvD2), carry out their pro-resolving functions by directly binding to class A G protein-coupled receptors FPR2/ALXR and GPR32, and GPR18, respectively. We recently demonstrated that RvD1 and RvD2 preferentially partition and accumulate at the polar headgroup regions of the membrane. However, the mechanistic detail of how RvD1 gains access to the FPR2 binding site from a surrounding membrane environment remains unknown. In this study, we used classical MD and well-tempered metadynamics simulations to examine the structural basis for the access and binding of RvD1 to its target receptor from aqueous and membrane environments. The results offer valuable insights into the access path, potential binding pose, and key residue interactions essential for the access and binding of RvD1 to FPR2/ALXR and may help in identifying small molecule therapeutics as a possible treatment for inflammatory disorders.
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Resolvin D-series regulates Phospholipase D both during inflammation and resolution by modulating phagocyte functions
R. Ganesan, K. M. Henkels, … J. G. Cambronero·bioRxiv·Nov 2, 2019
- Divergent activation of the RXFP1 relaxin receptor by protein and small molecule agonists
James Osei‐Owusu, Tristan Girbau, … Andrew C. Kruse·bioRxiv·Jun 11, 2026
- Structural insights into the modes of relaxin-binding and tethered-agonist activation of RXFP1 and RXFP2
A. Sethi, S. Bruell, … P. R. Gooley·bioRxiv·Jun 6, 2021
- The relaxin receptor RXFP1 signals through a mechanism of autoinhibition
S. C. Erlandson, S. Rawson, … A. C. Kruse·bioRxiv·Jan 22, 2022
- Developing selective FPR2 agonists can be a potential approach to treat moderate to severe asthma.
S. A. Visaga, H. Kalonia, … R. Tandon·bioRxiv·Sep 16, 2021
- Conformational dynamics of the active state of β-arrestin 1
Van A. Ngo, Wesley B. Asher, … Lei Shi·bioRxiv·Jun 10, 2025